News
-
Lightlake Therapeutics has agreed to license its intranasal naloxone for opioid overdose reversal to Adapt Pharma for possible development and sales milestones of more than $55 million, plus royalties, the company said. Lightlake recently announced… Read more . . .
-
GSK has announced that it will change the color of the Relvar Ellipta fluticasone/vilanterol DPI starting in January 2015. The company said that it will remove the color blue from the inhaler and its packaging… Read more . . .
-
Acorda Therapeutics has announced the enrollment of the first patient in a Phase 3 study of CVT-301 inhaled L-dopa for the treatment of OFF episodes in Parkinson’s disease (PD). The study is expected to enroll… Read more . . .
-
Cystic Fibrosis Foundation Therapeutics (CFFT), a nonprofit associated with the Cystic Fibrosis Foundation, has announced that it will provide Shire with up to $15 million for development of an aerosol messenger RNA therapy designed to… Read more . . .
-
Submit podium abstracts by March 9, 2015 and poster abstracts by May 9 2015 at http://www.inhalationasia.org/conference/inhalation-asia-15/present. Inhalation Asia offers open access to its conference archive; authors must consent to making presentations and/or posters available at… Read more . . .
-
Pfizer has launched Novartis’ Ultibro Breezhaler indacaterol/glycopyrronium DPI for the treatment of COPD in the UK, the company said. Ultibro Breezhaler was approved in Europe in September 2013. In September 2014, Pfizer announced that it… Read more . . .
-
Submit 3-5 page double-space poster abstracts by January 9, 2015 online at http://www.rddonline.com/rdd/poster_reg.php?id=11. Poster guidelines can be found at http://www.rddonline.com/rdd/rdd.php?id=11&sid=4&sub=358 Read more . . .
-
RDD Online and Aptar Pharma have announced that registration is now open for Respiratory Drug Delivery (RDD) Europe 2015, to be held May 5-8, 2015 in Antibes, France. This will be the 10th anniversary of… Read more . . .
-
Lightlake Therapeutics has announced that it has begun a new trial of its intranasal naloxone for the reversal of opioid overdose. According to the company, it plans to file a New Drug Application with the… Read more . . .
-
PulmoFlow has announced that the FDA has approved its NDA for Kitabis Pak, generic tobramycin inhalation solution packaged with a PARI LC PLUS nebulizer, for the treatment P. aeruginosa infections in cystic fibrosis patients. PARI… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany